Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's episode of Five Must-Know Things: Leqembi’s US treatment infrastructure; Novartis backs out of BeiGene deal; Transgene’s new CEO’s plans; Japanese firms’ R&D success; and a look at deal-making in the first half.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 14 July 2023, including: Leqembi’s US treatment infrastructure; Novartis AG backs out of BeiGene, Ltd. deal; Transgene S.A.’s new CEO’s plans; Japanese firms’ R&D success; and a look at deal-making in the first half.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Leqembi Treatment Infrastructure: If Medicare Pays For It, They Will Come" - Scrip, 7 Jul, 2023.)
(Also see "Novartis Says No To TIGIT, Backs Out Of BeiGene Deal" - Scrip, 11 Jul, 2023.)
(Also see "Ex-Novartis Oncology Leader Riva Takes On Challenge Of Transgene Turnaround" - Scrip, 6 Jul, 2023.)
(Also see "What's Behind Japan Firms' Higher Approval Rates In Challenging Oncology, CNS Areas?" - Scrip, 11 Jul, 2023.)
(Also see "Despite Pfizer/Seagen’s Splash, Deals Are Staying Small" - Scrip, 12 Jul, 2023.)